Biotech · Private company
Akcea Therapeutics
Track this companyFree. Adds Akcea Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials121 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- volanesorsenPhase 3 · Familial Partial LipodystrophyClinicalTrials.gov · fetched Nov 12, 2026
- VolanesorsenPhase 3 · Familial Chylomicronemia SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- AKCEA-ANGPTL3-LRxPhase 2 · Familial Partial LipodystrophyClinicalTrials.gov · fetched Nov 12, 2026
- ISIS 678354Phase 2 · HypertriglyceridemiaClinicalTrials.gov · fetched Nov 12, 2026
- ISIS 681257Phase 2 · Elevated Lipoprotein(a)ClinicalTrials.gov · fetched Nov 12, 2026
- ISIS 703802 20 mgPhase 2 · NAFLDClinicalTrials.gov · fetched Nov 12, 2026
- ISIS 703802 40 mgPhase 2 · NAFLDClinicalTrials.gov · fetched Nov 12, 2026
- ISIS 703802 80 mgPhase 2 · NAFLDClinicalTrials.gov · fetched Nov 12, 2026
- ISIS 681257Phase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- TEGSEDIHereditary Transthyretin Amyloidosis With PolyneuropthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PNPHASE4 · TERMINATED · started Jan 21, 2021ClinicalTrials.gov NCT04306510 · fetched Nov 12, 2026
- Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFNA · RECRUITING · started Oct 2, 2020ClinicalTrials.gov NCT05577819 · fetched Nov 12, 2026
- Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)PHASE2 · COMPLETED · started Jun 15, 2018ClinicalTrials.gov NCT03514420 · fetched Nov 12, 2026
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsPHASE1 · COMPLETED · started Mar 20, 2018ClinicalTrials.gov NCT03506854 · fetched Nov 12, 2026
- Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)PHASE2 · COMPLETED · started Jan 30, 2018ClinicalTrials.gov NCT03385239 · fetched Nov 12, 2026
- Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseasePHASE2 · COMPLETED · started Dec 21, 2017ClinicalTrials.gov NCT03371355 · fetched Nov 12, 2026
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseasePHASE2 · COMPLETED · started Mar 7, 2017ClinicalTrials.gov NCT03070782 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy VolunteersPHASE1 · COMPLETED · started Sep 19, 2016ClinicalTrials.gov NCT02910635 · fetched Nov 12, 2026
- The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial LipodystrophyPHASE2_PHASE3 · TERMINATED · started Dec 28, 2015ClinicalTrials.gov NCT02527343 · fetched Nov 12, 2026
- The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia SyndromePHASE3 · COMPLETED · started Dec 23, 2015ClinicalTrials.gov NCT02658175 · fetched Nov 12, 2026
- The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With HypertriglyceridemiaPHASE3 · COMPLETED · started Feb 5, 2015ClinicalTrials.gov NCT02300233 · fetched Nov 12, 2026
- The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia SyndromePHASE3 · COMPLETED · started Dec 1, 2014ClinicalTrials.gov NCT02211209 · fetched Nov 12, 2026